The states with the highest rates of HIV diagnoses in 2022 included Georgia, Louisiana, and Florida. However, the states with the highest number of people with HIV were Texas, California, and Florida. In Texas, there were around 4,896 people diagnosed with HIV. HIV/AIDS diagnoses In 2022, there were an estimated 38,043 new HIV diagnoses in the United States, a slight increase compared to the year before. Men account for the majority of these new diagnoses. There are currently around 1.2 million people living with HIV in the United States. Deaths from HIV The death rate from HIV has decreased significantly over the past few decades. In 2023, there were only 1.3 deaths from HIV per 100,000 population, the lowest rate since the epidemic began. However, the death rate varies greatly depending on race or ethnicity, with the death rate from HIV for African Americans reaching 19.2 per 100,000 population in 2022, compared to just three deaths per 100,000 among the white population.

In 2022, the states with the highest number of HIV diagnoses were Texas, California, and Florida. That year, there were a total of around 37,601 HIV diagnoses in the United States. Of these, 4,896 were diagnosed in Texas. HIV infections have been decreasing globally for many years. In the year 2000, there were 2.8 million new infections worldwide, but this number had decreased to around 1.3 million new infections by 2023. The number of people living with HIV remains fairly steady, but the number of those that have died due to AIDS has reached some of its lowest peaks in a decade. Currently, there is no functional cure for HIV or AIDS, but improvements in therapies and treatments have enabled those living with HIV to have a much improved quality of life.

United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data was reported at 0.500 % in 2014. This stayed constant from the previous number of 0.500 % for 2013. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data is updated yearly, averaging 0.500 % from Dec 2008 (Median) to 2014, with 7 observations. The data reached an all-time high of 0.500 % in 2014 and a record low of 0.500 % in 2014. United States US: Prevalence of HIV: Total: % of Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.; ; UNAIDS estimates.; Weighted Average;

United States US: Incidence of HIV: per 1,000 Uninfected Population data was reported at 0.110 Ratio in 2019. This stayed constant from the previous number of 0.110 Ratio for 2018. United States US: Incidence of HIV: per 1,000 Uninfected Population data is updated yearly, averaging 0.120 Ratio from Dec 2010 (Median) to 2019, with 10 observations. The data reached an all-time high of 0.130 Ratio in 2012 and a record low of 0.110 Ratio in 2019. United States US: Incidence of HIV: per 1,000 Uninfected Population data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Social: Health Statistics. Number of new HIV infections among uninfected populations expressed per 1,000 uninfected population in the year before the period.;UNAIDS estimates.;Weighted average;This is the Sustainable Development Goal indicator 3.3.1 [https://unstats.un.org/sdgs/metadata/].

In 2024, the number of diagnosed HIV cases in Mexico amounted to approximately 19,000. That year, the State of Mexico, Veracruz, and Mexico City were the federative entities with the highest number of people diagnosed with the human immunodeficiency virus (HIV), with more than 1,000 patients each. Moreover, most registered HIV cases in the Latin American country between 1984 and 2023 corresponded to men. People living with HIV in Latin America In the last few years, the number of people living with HIV in Latin America has been increasing. According to recent estimates, the number of individuals living with this condition rose from around 1.6 million in 2013 to almost 2.2 million by 2022. From a country perspective, Brazil and Mexico were the Latin American nations where most people were living with the disease, reaching approximately 990,000 and 370,000 patients, respectively. ART is more costly in Latin America HIV is commonly treated through antiretroviral therapy (ART), a drug-based treatment aimed at reducing the viral load in the blood to help control the development of the disease while improving the health of those infected. Although the share of deaths among people living with HIV due to causes unrelated to AIDS increased globally since 2010, there are still inequalities in the access to ART therapy. As of 2022, Latin America and the Caribbean recorded the highest average price per person for HIV antiretroviral therapy compared to other regions worldwide.

BackgroundIn the generalised epidemics of sub-Saharan Africa (SSA), human immunodeficiency virus (HIV) prevalence shows patterns of clustered micro-epidemics. We mapped and characterised these high-prevalence areas for young adults (15–29 years of age), as a proxy for areas with high levels of transmission, for 7 countries in Eastern and Southern Africa: Kenya, Malawi, Mozambique, Tanzania, Uganda, Zambia, and Zimbabwe.Methods and findingsWe used geolocated survey data from the most recent United States Agency for International Development (USAID) demographic and health surveys (DHSs) and AIDS indicator surveys (AISs) (collected between 2008–2009 and 2015–2016), which included about 113,000 adults—of which there were about 53,000 young adults (27,000 women, 28,000 men)—from over 3,500 sample locations. First, ordinary kriging was applied to predict HIV prevalence at unmeasured locations. Second, we explored to what extent behavioural, socioeconomic, and environmental factors explain HIV prevalence at the individual- and sample-location level, by developing a series of multilevel multivariable logistic regression models and geospatially visualising unexplained model heterogeneity. National-level HIV prevalence for young adults ranged from 2.2% in Tanzania to 7.7% in Mozambique. However, at the subnational level, we found areas with prevalence among young adults as high as 11% or 15% alternating with areas with prevalence between 0% and 2%, suggesting the existence of areas with high levels of transmission Overall, 15.6% of heterogeneity could be explained by an interplay of known behavioural, socioeconomic, and environmental factors. Maps of the interpolated random effect estimates show that environmental variables, representing indicators of economic activity, were most powerful in explaining high-prevalence areas. Main study limitations were the inability to infer causality due to the cross-sectional nature of the surveys and the likely under-sampling of key populations in the surveys.ConclusionsWe found that, among young adults, micro-epidemics of relatively high HIV prevalence alternate with areas of very low prevalence, clearly illustrating the existence of areas with high levels of transmission. These areas are partially characterised by high economic activity, relatively high socioeconomic status, and risky sexual behaviour. Localised HIV prevention interventions specifically tailored to the populations at risk will be essential to curb transmission. More fine-scale geospatial mapping of key populations,—such as sex workers and migrant populations—could help us further understand the drivers of these areas with high levels of transmission and help us determine how they fuel the generalised epidemics in SSA.

United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data was reported at 0.020 % in 2014. This stayed constant from the previous number of 0.020 % for 2013. United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data is updated yearly, averaging 0.030 % from Dec 2008 (Median) to 2014, with 7 observations. The data reached an all-time high of 0.030 % in 2012 and a record low of 0.020 % in 2014. United States US: Incidence of HIV: % of Uninfected Population Aged 15-49 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Number of new HIV infections among uninfected populations ages 15-49 expressed per 100 uninfected population in the year before the period.; ; UNAIDS estimates.; Weighted Average;

In 2023, Black or African Americans had the highest rates of HIV diagnoses among males in the United States. In that year, among all men, 19 per 100,000 were diagnosed with HIV. This statistic displays the rate of HIV diagnoses among males in the U.S. in 2023, by race and ethnicity (per 100,000 population).

All figures are given as % (95% CI) unless noted. There were 61 counties in the top decile and 551 in the remaining deciles.

Association between US ED characteristics and location in an HIV priority jurisdiction.

The size of the Prophylactic HIV Drugs Market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 4.10% during the forecast period. Prophylactic HIV drugs market is growing steadily with rising awareness about the necessity of preventive treatments. Most of these drugs represent pre-exposure prophylaxis (PrEP) drugs, which are designed to prevent HIV infection before it can take place in high-risk individuals. This market will be driven by increasing HIV rates in Africa, Asia, and some parts of the Americas, besides global efforts toward HIV prevention.The primary drugs that have been successful in the market are Truvada and Descovy, which have shown success in significantly lowering the transmission risk of HIV. Governmental efforts alongside awareness programs that motivate people to use PrEP have contributed much to the growth of the market mainly in well-developed countries with robust healthcare infrastructure. However, access in low-income regions and the cost of drugs, along with the stigma of HIV, continue to be huge challenges. The presence of generics and research on less expensive and longer-acting preventive treatments will help drive growth going forward.In a conclusive trend, the prophylactic HIV drugs market is expected grow with an expanding spread of knowledge and improved access, placing preventive treatment as one of the strategic approaches to global HIV management. Recent developments include: December 2022: The United State Food and Drug Administration (US FDA) approved Sunlenca (lenacapavir), a new type of antiretroviral medication for adult patients living with human immunodeficiency virus type 1 (HIV-1), whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations., In February 2022: The United State Food and Drug Administration (US FDA) approved rilpivirine and cabotegravir (Cabenuva) for 2-month dosing for adults living with HIV-1 infection.. Key drivers for this market are: High Prevalence of HIV/AIDS, Increasing Government Initiatives; Increasing R&D Activities. Potential restraints include: Lower Penetration in Underdeveloped Markets. Notable trends are: Oral Drug Forms Segment is Expected to Hold a Significant Share Over the Forecast Period.

United States US: Newly Infected with HIV: Children: Aged 0-14 data was reported at 200.000 Number in 2019. This stayed constant from the previous number of 200.000 Number for 2018. United States US: Newly Infected with HIV: Children: Aged 0-14 data is updated yearly, averaging 200.000 Number from Dec 2010 (Median) to 2019, with 10 observations. The data reached an all-time high of 500.000 Number in 2012 and a record low of 200.000 Number in 2019. United States US: Newly Infected with HIV: Children: Aged 0-14 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Social: Health Statistics. Number of children (ages 0-14) newly infected with HIV.;UNAIDS estimates.;;This indicator is related to Sustainable Development Goal 3.3.1 [https://unstats.un.org/sdgs/metadata/].

Objective: To examine if the rankings of state HIV age-standardized death rates (ASDRs) changed if different standard population (SP) was used. Design: A cross-sectional population-based observational study. Setting 36 states in the United States. Participants: People died from 2015 to 2019. Main outcome measures: State HIV ASDR using 4 SPs, namely WHO2000, US2000, US2mor020, and Eur2011–2030. Results: The rankings of 19 states did not change when ASDRs were calculated using US2000 and US2020. Of the 17 states whose rankings changed, the rankings of 9 states calculated using US2000 were higher than those calculated using US2020; in 8 states, the rankings were lower. The states with the greatest changes in rankings between US2000 and US2020 were Kentucky (12th and 9th, respectively) and Massachusetts (8th and 11th, respectively). Conclusions: State ASDRs calculated using the current official SP (US2000) weigh middle-age HIV death rates more heavily than older-age HIV death rates, resulting in lower ASDRs among states with higher older-age HIV death rates. Methods The data were extracted from CDC WONDER.

• Subtotal for those with known HIV status.** p value between HIV positive and HIV negative.117 out of 639 specimen was also culture positive for MAC; 7 in HIV positive group and 9 in HIV negative group.24 were also culture positive for M. gordonae, 10 with M. kansasii, 2 with Nocardia. All were found among HIV positive group.310 were also culture positive for MAC. All were from HIV positive group.44 were also culture positive for MAC>All were from HIV positive group.52 were also culture positive for MAC. All were from HIV positive group.Patient demographics and summary of microbiological data of the specimens, per specimen.

Note. Data include persons with diagnosed HIV infection regardless of stage of disease at diagnosis. HIV diagnosis data were statistically adjusted for missing transmission category, but not for reporting delays or incomplete reporting. All results for each outcome of interest in the models are based on controlling for all other variables.MSM, men who reported ever having had sexual contact with other men.CI, confidence interval.aBlack non-MSM is the reference group.bThe prevalence odds is defined as (#MSM+1)/(#non-MSM+1), where adding 1 to both the numerator and the denominator avoids the prevalence odds undefined when there are no diagnosed HIV infections among black non-MSM. PORs>1 indicates that among black males, as the proportion of a SDH variable of interest increases, the probability of black MSM diagnosed with HIV is higher compared to black non-MSM.Prevalence odds ratiosa of HIV infection diagnosis for black/African American MSM vs. non-MSM, by selected census tract-level social determinants of health (SDH), 2005–2009—17 areas.

In 2023, the death rate from HIV was highest among African Americans, with around 18 deaths per 100,000 population. This statistic shows the death rate from HIV in the U.S. in 2023, by race and ethnicity, per 100,000 population.

Among all countries worldwide those in sub-Saharan Africa have the highest rates of HIV. The countries with the highest rates of HIV include Eswatini, Lesotho, and South Africa. In 2023, Eswatini had the highest prevalence of HIV with a rate of around ** percent. Other countries, such as Zimbabwe, have significantly decreased their HIV prevalence. Community-based HIV services are considered crucial to the prevention and treatment of HIV. HIV Worldwide The human immunodeficiency virus (HIV) is a viral infection that is transmitted via exposure to infected semen, blood, vaginal and anal fluids and breast milk. HIV destroys the human immune system, rendering the host unable to fight off secondary infections. Globally, the number of people living with HIV has generally increased over the past two decades. However, the number of HIV-related deaths has decreased significantly in recent years. Despite being a serious illness that affects millions of people, medication exists that effectively manages the progression of the virus in the body. These medications are called antiretroviral drugs. HIV Treatment Generally, global access to antiretroviral treatment has increased in recent years. However, despite being available worldwide, not all adults have access to antiretroviral drugs. Europe and North America have the highest rates of antiretroviral use among people living with HIV. There are many different antiretroviral drugs available on the market. As of 2024, ********, an antiretroviral marketed by Gilead, was the leading HIV treatment based on revenue.

United States US: Children: 0-14 Living with HIV data was reported at 2,500.000 Person in 2019. This records a decrease from the previous number of 2,800.000 Person for 2018. United States US: Children: 0-14 Living with HIV data is updated yearly, averaging 3,700.000 Person from Dec 2010 (Median) to 2019, with 10 observations. The data reached an all-time high of 4,700.000 Person in 2010 and a record low of 2,500.000 Person in 2019. United States US: Children: 0-14 Living with HIV data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Social: Health Statistics. Children living with HIV refers to the number of children ages 0-14 who are infected with HIV.;UNAIDS estimates.;;

United States US: Newly Infected with HIV: Adults: Aged 15-24 data was reported at 5,600.000 Number in 2021. This records a decrease from the previous number of 5,900.000 Number for 2020. United States US: Newly Infected with HIV: Adults: Aged 15-24 data is updated yearly, averaging 7,200.000 Number from Dec 2010 (Median) to 2021, with 12 observations. The data reached an all-time high of 10,000.000 Number in 2010 and a record low of 5,600.000 Number in 2021. United States US: Newly Infected with HIV: Adults: Aged 15-24 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Social: Health Statistics. Number of young people (ages 15-24) newly infected with HIV.;UNAIDS estimates.;;This indicator is related to Sustainable Development Goal 3.3.1 [https://unstats.un.org/sdgs/metadata/].

BackgroundIndian guidelines recommend routine referral for HIV testing of all tuberculosis (TB) patients in the nine states with the highest HIV prevalence, and selective referral for testing elsewhere. We assessed the clinical impact and cost-effectiveness of alternative HIV testing referral strategies among TB patients in India.Methods and FindingsWe utilized a computer model of HIV and TB disease to project outcomes for patients with active TB in India. We compared life expectancy, cost, and cost-effectiveness for three HIV testing referral strategies: 1) selective referral for HIV testing of those with increased HIV risk, 2) routine referral of patients in the nine highest HIV prevalence states with selective referral elsewhere (current standard), and 3) routine referral of all patients for HIV testing. TB-related data were from the World Health Organization. HIV prevalence among TB patients was 9.0% in the highest prevalence states, 2.9% in the other states, and 4.9% overall. The selective referral strategy, beginning from age 33.50 years, had a projected discounted life expectancy of 16.88 years and a mean lifetime HIV/TB treatment cost of US$100. The current standard increased mean life expectancy to 16.90 years with additional per-person cost of US$10; the incremental cost-effectiveness ratio was US$650/year of life saved (YLS) compared to selective referral. Routine referral of all patients for HIV testing increased life expectancy to 16.91 years, with an incremental cost-effectiveness ratio of US$730/YLS compared to the current standard. For HIV-infected patients cured of TB, receiving antiretroviral therapy increased survival from 4.71 to 13.87 years. Results were most sensitive to the HIV prevalence and the cost of second-line antiretroviral therapy.ConclusionsReferral of all patients with active TB in India for HIV testing will be both effective and cost-effective. While effective implementation of this strategy would require investment, routine, voluntary HIV testing of TB patients in India should be recommended.